ENCEPHALOMYELITIS/EAE – a mouse multiple sclerosis model

 

Suppression of experimental autoimmune encephalomyelitis by cannabinoids. (abst – 1997)                                            http://www.ncbi.nlm.nih.gov/pubmed/7852052

 

Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55,212           (full – 2003)

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC152941/?tool=pmcentrez

 

Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation.       (abst – 2005)                               http://www.ncbi.nlm.nih.gov/pubmed/15953683

 

Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection          (full – 2006)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1458883/?tool=pmcentrez

 

The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis                                          ( full – 2007)  http://brain.oxfordjournals.org/cgi/content/full/awm160v1

 

 

 

 

 

 

 

 

Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors          (full – 2007)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2189718/?tool=pmcentrez

 

CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies                                                                       (full – 2007)  http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2219542&tool=pmcentrez

 

A Cannabinoid CB2 receptor agonist attenuates experimental autoimmune encephalomyelitis (EAE) and reduces MOG-specific T cell proliferation                                                                            (abst – 2007)  http://www.fasebj.org/cgi/content/meeting_abstract/21/6/A1393-  c?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=800&  resourcetype=HWCIT

 

The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis.                                                    (full – 2008)  http://www.jbc.org/content/283/19/13320.long

 

CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies                                                                          (full – 2008)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219542/

 

Cannabinoids in the management of spasticity associated with multiple sclerosis (full – 2008)                                    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2626929/?tool=pmcentrez

 

Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke.            (full – 2009)

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855650/?tool=pubmed

 

Administration of 2-arachidonoylglycerol ameliorates both acute and chronic Experimental Autoimmune Encephalomyelitis                                                              (abst – 2011)  http://www.unboundmedicine.com/medline/ebm/record/21406188/abstract/Administration_of_2_arachidon  oylglycerol_ameliorates_both_acute_and_chronic_Experimental_Autoimmune_Encephalomyelitis_

 

Cannabinoid receptor-2-selective agonists improve recovery in experimental autoimmune encephalomyelitis                                                (abst – 2012)  http://www.jimmunol.org/cgi/content/meeting_abstract/188/1_MeetingAbstracts/116.7?maxtoshow=&hits

=25&RESULTFORMAT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=130&sortspec=date&resou  rcetype=HWCIT

 

Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB(1) receptor-mediated anti-inflammatory effects. (abst – 2012)   http://www.ncbi.nlm.nih.gov/pubmed/22342378

 

Cannabinoid receptor 2 agonists inhibit migration of activated dendritic cells via modulation of MMP-9 (abst – 2012)  http://www.jimmunol.org/cgi/content/meeting_abstract/188/1_MeetingAbstracts/173.23?maxtoshow=&hit       s

=25&RESULTFORMAT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=130&sortspec=date&resou  rcetype=HWCIT

 

 

 

 

 

 

 

 

 

Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis.    (abst – 2012)  http://www.unboundmedicine.com/medline/ebm/record/22928118/abstract/Evaluation_of_the_Effects_of_

 

Share a link for